Medistim ASA 2025 AR2
The report highlights Medistim's record performance in fiscal year 2025, achieving NOK 700 million in sales and a 28% EBIT margin. The company advanced its global commercial operations, launched the new INTUI software for the MiraQ Cardiac system, and progressed with the PATENT study in peripheral bypass surgery. In terms of sustainability, Medistim conducted a double materiality assessment aligned with ESRS methodology, initiated carbon footprint data collection under the GHG Protocol, and prepared for compliance with the voluntary VSME standard. The company also maintained a strong focus on product quality, safety, and employee well-being, reporting zero work-related injuries in 2025.
Company: Medistim ASA
Sector: Manufacturing
Country: Norway
Year: 2025
Type: AR2
Pages: 124
Back to company
Medistim ASA
Corporate Annual Report
The report highlights Medistim's record performance in fiscal year 2025, achieving NOK 700 million in sales and a 28% EBIT margin. The company advanced its global commercial operations, launched the new INTUI software for the MiraQ Cardiac system, and progressed with the PATENT study in peripheral bypass surgery. In terms of sustainability, Medistim conducted a double materiality assessment aligned with ESRS methodology, initiated carbon footprint data collection under the GHG Protocol, and prepared for compliance with the voluntary VSME standard. The company also maintained a strong focus on product quality, safety, and employee well-being, reporting zero work-related injuries in 2025.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees